Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Bull Horn Holdings (BHSEU)
New Beginnings Acquisition (NBA.U)
CONX (CONXU)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Cerberus Telecom Acquisition (CTACU)
Upcoming IPO
OTR Acquisition (OTRAU)
Natural Order Acquisition (NOACU)
Priced IPO
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
More companies

Taysha Gene Therapies, Inc. (TSHA)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. They were founded in partnership with The University of Texas Southwestern Medical Center, or UT Southwestern, to develop and commercialize transformative gene therapy treatments. Together with UT Southwestern, they are advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs at no cost. By combining their management team’s proven experience in gene therapy drug development and commercialization with UT Southwestern’s world-class gene therapy research capabilities, they believe they have created a powerful engine to develop transformative therapies to dramatically improve patients’ lives. They expect to initiate a Phase 1/2 clinical trial of TSHA-101 for the treatment of GM2 gangliosidosis, under a Clinical Trial Application, or CTA, in Canada by the end of 2020. In addition, they plan to submit INDs for four programs to the FDA by the end of 2021.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
RA Session II Kamran Alam
Employees Founded
10 2019

Contacts

Address: 2280 Inwood Road Dallas, TX 75235

Telephone: (214) 612-0000

Web page: http://www.tayshagtx.com

IPO information

Expected Date 9/24/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $657.2
Revenues (MM) $0
Net Income (Loss) (MM) $-26.7

Voting

What do you think will happen with the TSHA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 6.6
Shares Revised (MM) 7.9
Expected offer amount (MM) $125.4
Realized offer amount(MM) $158
Underwriters
Goldman Sachs/ Morgan Stanley/ Jefferies
CO-Managers
Chardan

Sector: Healthcare

Tweets about $TSHA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats